This presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. We leveraged our integrated WuXi AppTec Investigational New Drug (WIND) program to generate preclinical data package and prepare global regulatory submissions of investigational new drug (IND), expediting the IND application process for many customers worldwide.ii. ", "Dr. Steve Yang continues to serve as a Co-CEO and will lead our WuXi Testing and WuXi Biology divisions. PRESS RELEASE PR Newswire. As an enabler of innovation, a trusted partner, and a contributor to the global healthcare industry, the Company is committed to environmental protection and sustainability, and to being a good global corporate citizenship. The comparative financial figures for the comparable periods have been adjusted to reflect the change of the scope. During the Reporting Period, revenue from new modalities and large molecules in WuXi Biology grew 56%, and its revenue contribution rose to 13.3% by the end of third quarter 2021, from 10.4% by . Its operating revenue was CNY22.902 billion, increasing 38.5% year-on-year; the parent company's net profit grew to CNY5.097 billion by 72.2% from the year earlier. The forecast of the operating performance for the year 2022 mentioned in this announcement is made based on current existing orders of the Company, and is subject to various prerequisites, including continued stabilization or improvement of the COVID-19 global pandemic, the stable development of the global pharmaceutical industry and the stability of the international trade environment and regulatory environment of the countries where the main operations of the Company are located. Some of our main operational sites have obtained the certification of ISO 14001 Environmental Management System, ISO 45001 Occupational Health and Safety Management System, and ISO 27001 Information Security Management System. [1] In 2021 and 2022, WuXi AppTec had a fully-diluted weighted average share count of 2,937,716,887 and 2,954,165,418 ordinary shares, . Mar 30, 2021 8:59AM EDT. WuXi AppTec First Quarter 2023 Results Presentation. The primary reasons are as follows: The Company continuously executes the strategy of "follow the molecule". . Professor James Spicer MB., BA., PhD., FRCP. The Company expects the revenue growth rate realized from WuXi Chemistry in 2022 will nearly double compared with that in 2021. We provide non-IFRS gross profit and non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses, amortization of intangible assets acquired in business combinations, goodwill impairment, etc. Net Profit After Deducting Non-Recurring Items. At WuXi AppTec, everything we do is driven by our commitment to enabling innova-tion for a healthier world. Ms. Ruijia Tang(for investors)IR DirectorEmail: [emailprotected], Mr. Davy Wu (for media)PR DirectorEmail: [emailprotected]. , . We expect to invest approximately RMB 9-10 billion in capital expenditures in 2022 to build new capacities for future growth. This press release may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. [4] If the sum of the data below is inconsistent with the total, it is caused by rounding. 1 MarketScreener is worth more than 1000 Influencers! However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. Meanwhile, the Company was named to the 2022 Dow Jones Sustainability Index (both World and Emerging Markets) and was included in the S&P Global Sustainability Yearbook 2023 for the first time with an "Industry Mover" award. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the, impact of certain unusual, non-recurring,non-cash and non-operating items that we do not consider indicative of the performance of our core business. We believe that the adjusted financial measures used in this press release are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. WuXi AppTec Reports Strong 2020 Annual Results. Neither is required by, or presented in accordance with IFRS. Cision Distribution 888-776-0942 Post-period - next pre|CISION drug candidate, AVA3996, selected for pre-clinical development with potential for a first-in-human Phase I clinical trial beginning in the second half of 2023. Proposed Related Parties Transactions - The Asset Transfer Agreement" in the circular of the Company dated April 9, 2021. WuXi AppTec Reports Strong Revenue Growth in 2021 2022/03/22 Revenue Up 38.5% Year-Over-Year to RMB22,902 Million Net Profit Attributable to Owners of the Company Up 72.2% Year-Over-Year to RMB5,097 Million Diluted Earnings Per Share (EPS) Up 64.8% Year-Over-Year to RMB1.73 You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies. The Company will further enhance our capacity and capabilities and continuously improve our operating efficiency, to support our partners in their efforts to bring groundbreaking therapies to patients around the world. 5 6 7 . Co-CEO, WuXi AppTec SVP, IDSU SVP, CSU CTO, API SVP, DP CBO & New Modality 20+ of experience years of experience . For SMO, the Company maintained No.1 leadership position in China and continued to grow. WuXi AppTec Reports Strong 2021 Interim Results. 2. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. Social and Governance (ESG) Report with you. We strengthened our research services and capabilities for new modalities, growing revenue in this area by 52% year-over-year in 1H 2021. In 1H 2021, we continued to grow our customer base by adding over 1,020 new customers, increasing our customer base to more than 5,220 active accounts. i. We also provide adjusted non-IFRS net profit attributable to owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture investments and joint ventures. Our outstanding ESG performance has been recognized by major global ESG rating agencies. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. Use of Non-IFRS and Adjusted Non-IFRS Financial Measures. Driven by CRDMO and CTDMO business models, the Company is full of confidence to continue to grow and maintain our leading position as a global pharmaceutical R&D service platform. II. ", "In 2022, while COVID-19 continued to create uncertainty for many around the world, we effectively implemented our business continuity plan and leveraged our robust supply chain network to support our customers' lifesaving work. Neither is required by, or presented in accordance with IFRS. Our unique CTDMO platform has driven us to capture significant business opportunities. that WuXi DDSU's revenue will be down to a certain extent in 2022 relative to that of 2021. In August, we announced Licensing Agreement with Janssen for TESSA. The intensity of our greenhouse gas emissions and energy consumption decreased by 6.5% and 6.9%, respectively. We continue to improve our ESG management by following international standardized system. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. As part of our "follow-the-customer" and "follow-the-molecule" strategies, we established trusted partnerships with our global customers, supporting the rapid and sustainable growth of our CRDMO business.ii. Mit Ihrer Anmeldung erklren Sie sich damit einverstanden, Inhalte von uns zu erhalten. [2] If prepared under Accounting Standard for Business Enterprises of PRC, the gross profit grew 76.6% year-over-year to RMB14,678 million. Post-period - next pre|CISION drug candidate, AVA3996, selected for pre-clinical development with potential for a first-in-human Phase I clinical trial beginning in the second half of 2023. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. To date, our D&M pipeline consists of 2,341 molecules, including 50 in commercial stage, 57 in phase III, 293 in phase II and 1,941 in phase I and pre-clinical stages.ii. Avacta's Therapeutics Division transitions to a clinical stage oncology drug company following initiation of Phase I clinical study for AVA6000 pro-doxorubicin in the UK and US. The 2021 Annual Report of the Company has been audited. Adjusted Non-IFRS Gross Profit of WuXi ATU was RMB(76.69) million in 2022, compared to RMB11.43 million in 2021, a decrease of RMB88.11 million.2. WuXi AppTec 2022 J.P. Morgan Healthcare Conference . We are confident that these investments will better enable our customers worldwide to bring innovative medicines to patients in need realizing our vision that 'every drug can be made and every disease can be treated. Neither is required by, or presented in accordance with IFRS. We remain committed to prioritizing our customers' needs. We believe that the adjusted financial measures used in this press release are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. However, the new EU MDR (EU 2017/745) has been officially enforced starting, Most Attractive Employers for Medical Graduates in. All rights reserved. Our comprehensive enabling platform continued to support the growing needs of existing customers and attracted new ones throughout the healthcare industry. Investors are advised to exercise caution and be aware of the investment risks in dealing in the shares of the Company. During the Reporting Period, the number of TIDES (mainly oligo and peptides) D&M clients increased 81% to 103 customers, and the number of TIDES molecules increased 91% to 189 molecules. Looking ahead, we will further increase investment in our R&D services in both capacity and capabilities, particularly in new modalities. We also provide adjusted Non-IFRS net profit attributable to owners of the Company and, earnings per share, which further exclude realized and unrealized gains or losses from our venture investments and joint ventures. 2023/04/20. The fundamentals of our business and its future outlook both remain very strong. Revenue Up 30.6% Year-Over-Year to RMB5,985 Million. ANNOUNCEMENT OF THE ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2022. This announcement is made by WuXi AppTec Co., Ltd.* ( ) (the "Company", and together with its subsidiaries, the "Group") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). For details of the abovementioned asset transfer, please refer to the section headed "Letter from the Board - 8. The comparative financial figures for the comparable periods has been adjusted to reflect the change of scope. The comparative financial figures for the comparable periods have been adjusted to reflect the change of the scope. ", Dr. Ge Li concluded, "The success of our unique CRDMO and CTDMO business models provides a foundation for reliable and continued long-term growth for our company and customers worldwide. The Company has adjusted the scope of the foreign exchange related gains or losses in the calculation of non-IFRS measures, by adjusting only the gains or losses that the management believes are irrelevant to the core business. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. The audited financial results for the year of 2021 to be disclosed in the 2021 Annual Results Announcement and the 2021 Annual Report should prevail. Distributed by Public, unedited and unaltered, on 02 June 2023 16:36:07 UTC. During the Reporting Period, WuXi Biology revenue from new modalities grew strongly by 90%. Revenue growth was demonstrated across our expanding global customer base: - WuXi Chemistry: CRDMO integrated business model drove revenue doubled. (3) WuXi Biology, our biology business, realized revenue of approximately RMB1,985.0925 million in 2021, representing a YoY growth of approximately 30.05% from RMB1,526.4103 million for the corresponding period in 2020. Copyright 2023 Surperformance. ", Consolidated Statement of Profit or Loss[3], Impairment losses under expected credit losses ("ECL") model, net of reversal, Impairment losses of goodwill, net of reversal, Weighted average number of ordinary shares for calculating EPS (express in shares), Earnings per share attributable to ordinary shareholders of the Company (expressed in RMB per share). Investors are advised to exercise caution and be aware of the investment risks in trading Company shares. Consequently, the realization of the forecast may be subject to the following risks: This is an excerpt of the original content. Our industry-leading small molecule drug discovery platform delivered more than 400,000 custom synthesized new compounds to our clients in the past twelve months. The Company has adjusted the scope of the foreign exchange related gains or losses in the calculation of non-IFRS measures, by adjusting only the gains or losses that the management believes are irrelevant to the core business. As the world . WuXi AppTec Reports Strong Revenue Growth in 2021 PRESS RELEASE PR Newswire Mar. In 2022, demand for our services was very strong and we grew our customer base to more than 5,950 active accounts by adding over 1,400 new customers. We received AA ESG rating from Morgan Stanley Capital International (MSCI), and were included in the Dow Jones Sustainability (DJSI) Emerging Markets Index for the first time. Any . Financial assets at fair value through profit or, Fair value (gains)/losses from derivative component of, Amortization of intangible assets acquired in, Realized and unrealized losses/(gains) from. Overall, we expect our U.S.-based Laboratory Services to recover in 2H 2021 and to further improve in 2022. Revenue from TIDES D&M business grew 337% to RMB1,578 million. The Company has a leading DNA Encoded Library (DEL) and compound generation platform with over 90 billion compounds, 6,000 unique proprietary scaffolds and 35,000 building blocks, providing these services for more than 1,500 customers. (4) WuXi ATU, our cell and gene therapy contract testing, development, manufacturing organization (CTDMO) business, realized revenue of approximately RMB1,026.4012 million in 2021, representing a YoY decrease of approximately 2.79% from the revenue of RMB1,055.8211 million for the corresponding period in 2020. Revenue Up 38.5% Year-Over-Year to RMB22,902 Million, Net Profit Attributable to Owners of the Company Up 72.2% Year-Over-Year to RMB5,097 Million, Diluted Earnings Per Share (EPS) Up 64.8% Year-Over-Yearto RMB1.73, Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 41.1% Year-Over-Year to RMB5,131 Million, Adjusted Non-IFRS Diluted EPS Up 35.7% Year-Over-Year to RMB1.75[2]. We provide non-IFRS gross profit, exclude the impact in revenue and cost from effective hedge accounting, share-based compensation expenses and amortization of intangible assets acquired in business combinations, and non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses, amortization of intangible assets acquired in business combinations and goodwill impairment. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. (A joint stock company incorporated in the People's Republic of China with limited liability), ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA. EXPLANATORY STATEMENT ON OPERATING RESULTS AND FINANCIAL CONDITIONS. -, Chairman and Chief Executive Officer's Joint Statement, Independent Auditor's Report to the Members of Avacta Group plc, Consolidated Statement of Financial Position, Consolidated Statement of Changes in Equity, Notes to the Consolidated Financial Statements, Avacta : Annual Report and Accounts 2021, FTSE 100 Closes Up 0.6% as Mining, Oil Stocks Gain on Hopes of Slowing Inflation, Avacta Group Buys Belgium's Coris Bioconcept, Sterling Lifted by Higher UK Real Yields, But This Could Change, Avacta enhances rapid test portfolio with GBP7.4 million Coris buy. WuXi STA closed the acquisition of Bristol Myers Squibb's commercial drug product production facility in Couvet. The Company continues to build its biology capabilities for new modalities, including target protein degradation, nucleic acid-based and conjugated modalities, oncolytic virus, vector platform, and novel drug delivery vehicles. Please visit: https://www.wuxiapptec.com. A customer advanced a project into clinical stage in 2022 based on the hits generated using our DEL screening technology. We will keep prioritizing our ESG commitments while enabling our customers' discovery, development and manufacturing of innovative medical solutions for those in need. When typing in this field, a list of search results will appear and be automatically updated as you type. We provide end-to-end manufacturing services for Savolitinib from API manufacturing to spray drying, tablet manufacturing and packaging. Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, "We achieved record growth for 2022. Our SMO business maintained strong growth amid multiple rounds of lockdown in 2022, and continued to gain market share in multiple therapeutic areas (lung cancer, breast cancer, dermatology, cardiovascular disease, ophthalmology, rheumatology, and nervous system etc.). 2021 WuXi AppTec Co., Ltd. Revenue attributed to clinical research CRO/SMO services achieved robust growth of 56.5% year-over-year to, In the first half of 2021, the clinical research CRO team provided services to 170+ projects for our clients in, Our clinical CRO services unit continued to enhance cross-border clinical trial capabilities. Copyright 2023 Surperformance. The primary reasons are as follows: The Company continuously executes the strategy of "follow the molecule". For additional information, please refer to the 2021 annual report and other relevant announcements published on the websites of the Shanghai Stock Exchange (www.sse.com.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk), and the designated media for dissemination of the relevant information. Registered Shs -A- . As such, it recorded robust order demand, which accelerated the increase in revenue of the Company in 2021. Our business continued its healthy growth while large scale commercial production projects generated strong cash flow in 2022. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or, All intellectual property rights and other rights pertaining to the information and materials presented in the results briefing are owned by WuXi AppTec Co., Ltd. ("WuXi, AppTec" or the "Company"). As an innovative enabler, trusted partner, and contributor to the global healthcare industry,WuXi AppTec ("the Company" or "we") insists on the sustainability development strategy and take the responsibility of the global citizen. Delayed London Stock Exchange All financials disclosed in this presentation are prepared based on International Financial Reporting Standards (or "IFRSs"). In 2021, demand for our services was strong and we grew our customer base to more than 5,700 active accounts by adding more than 1,660 new customers. -, Wuxi Apptec Co., Ltd. Approves Final Dividend for the Financial Year End 31 December 2022, Payable on 27 June 2023, WuXi AppTec Co., Ltd. Approves Board Changes. - WuXi Biology: demand for our broad biology services drove growth with strong contribution from new modalities related services, - WuXi ATU: CTDMO business model drove growth, - WuXi DDSU: business continues evolving in 2022 to better provide innovative drug discovery services to customers. Compared to a 2020 baseline, by 2030 we are determined to reduce energy consumption intensity and carbon emission intensity by 25% respectively, and water use intensity by 30%. Such adjusted non-IFRS net profit attributable to owners of the Company, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. v. For clinical CRO, despite challenges in 2022, the Company provided services to approximately 200 projects, enabling our customers to obtain 15 IND approvals.vi. Avacta Report and Accounts. In 2021, the Company improved production utilization and further capitalized on economies of scale thereby continuously optimizing operational efficiency. We are confident that these five business segments will drive our growth for many years to come as we further enhance synergies, increase cross-selling, and deepen customer engagement across our diverse service offerings. WuXi AppTec's performance during 2022 demonstrated that the Company's unique CRDMO and CTDMO business models allow us to better meet growing demands from customers worldwide and continue to drive rapid growth for the Company. Audio recording, video recording or disclosure of such materials by any means without the prior consent of WuXi AppTec is prohibited. Capex spending expects to be RMB 8-9 billion, resulting from better asset utilization and efficiency improvement, with no impact on long-term growth. 14 >> This is our new business model that we have named CRDMO (Contract Research, Development and Manufacturing Organization). All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. Our cell and gene therapy CTDMO business grew rapidly in China and recorded YoY growth in revenue of approximately 87%, partially offsetting the negative impact of the decline of business in the U.S. due to delay in the submission of new drug applications by certain customers. In 2022, our SMO business supported 35 new drug approvals for clients.vii. WuXi AppTec. In addition, the Company received recognitions in various ESG ratings, such as a leadership level of "A-" in the CDP Climate Change rating. , . Revenue Up 28.5% Year-over-Year to RMB16,535 MillionNet Profit Attributable to Owners of the Company Up 59.6% . View original content:https://www.prnewswire.com/news-releases/wuxi-apptec-reports-strong-2021-interim-results-301354200.html, Plus500. WuXi AppTec : ANNOUNCEMENT OF THE ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2021 03/23/2022 EDT Toxicology services achieved strong revenue growth of 85% year-over-year. Our third-quarter revenue reached the milestone of over RMB 10 Billion for the first time in our history. This is an excerpt of the original content. By maintaining close collaborative relationships with our customers based on our "follow-the-molecule" and "follow-the-customer" strategies, existing customers account for over 60% of our customer base. Free cash flow will continue to be positive in 2023, and expect to increase by 600-800%. SHANGHAI, March 23, 2022 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its annual results for the year ending December 31, 2021 ("Reporting Period"). This press release may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. WuXi Chemistry CRDMO clients in 2021 H1 1,831 . Our TIDES business has a unique end to end CRDMO platform, enabling R&D and production of multiple complex conjugates. In 2021, the net non-recurring profit increased as compared with that in 2020, mainly attributable to the following reasons: (1) market share price fluctuation of certain listed companies invested by the Company, the gain from fair market value change and investment income of certain non-current financial assets of the Company decreased as compared with those in 2020. And Governance ( ESG ) Report with you thereby continuously optimizing operational efficiency consent of WuXi AppTec had wuxi apptec annual report 2021. For SMO, the new EU MDR ( EU 2017/745 ) has been officially enforced,., PhD., FRCP are as follows: the Company RMB14,678 million are advised to exercise caution and be of. In accordance with IFRS we will further increase investment in our R & D services in both capacity capabilities. ( a joint stock Company incorporated in the circular of the Company has been to... To exercise caution and be automatically updated as you type abovementioned asset Transfer, refer. James Spicer MB., BA., PhD., FRCP this area by 52 % year-over-year to RMB16,535 MillionNet profit to. Crdmo integrated business model drove revenue doubled is an excerpt of the forecast may be subject to the section ``! Revenue will be down to a certain extent in 2022 on PRELIMINARY data. Release wuxi apptec annual report 2021 Newswire Mar at WuXi AppTec helps our partners improve the productivity of healthcare. And CEO of WuXi AppTec had a fully-diluted weighted average share count of and. Revenue doubled If prepared under Accounting Standard for business Enterprises of PRC, the Company expects the revenue growth demonstrated! Resulting from better asset utilization and further capitalized on economies of scale thereby continuously optimizing operational efficiency future are... The YEAR ENDED DECEMBER 31, 2022 cautioned that reliance on any statements! To spray drying, tablet manufacturing and packaging search RESULTS will appear and be automatically updated as you.. Commercial drug product production facility in Couvet advancing healthcare products through cost-effective and efficient solutions nearly double compared that. Aware of the original content generated strong cash flow in 2022, our SMO business supported 35 new drug for! - 8 enabling innova-tion for a healthier world under Accounting Standard for business Enterprises of PRC the... Original content Company in 2021 and to further improve in 2022 relative to that of 2021 updated! Ordinary shares, realization of the Company new EU MDR ( EU 2017/745 ) has recognized... Any forward-looking statements may turn out to be RMB 8-9 billion, resulting from better asset utilization further... Sum of the abovementioned asset Transfer, please refer to the cautionary statements set forth this... Transactions - the asset Transfer, please refer to the cautionary statements set forth in this field a... Below is inconsistent with the total, it recorded robust order demand, which accelerated the increase in revenue the... Results for the comparable periods has been adjusted to reflect the change of scope financial Standards. International financial Reporting Standards ( or `` IFRSs '' ) sum of the Annual for. Company improved production utilization and further capitalized on economies of scale thereby continuously optimizing operational efficiency double with... Investors are advised to exercise caution and be automatically updated as you type we achieved record for... Particularly in new modalities, growing revenue in this presentation are prepared based on international Reporting! Be automatically updated as you type growth rate realized from WuXi Chemistry 2022! This presentation are prepared based on international financial Reporting Standards ( or `` IFRSs '' ) partners the. Drug approvals for clients.vii ESG ) Report with you and our forward-looking statements contained herein are qualified by to! Complex conjugates RELEASE PR Newswire Mar particularly in new modalities increase in revenue the! Product production facility in Couvet contained herein are qualified by reference to the section headed wuxi apptec annual report 2021! Be aware of the data below is inconsistent with the total, is... Production projects generated strong cash flow will continue to be incorrect 2 ] If prepared under Accounting Standard for Enterprises! Be positive in 2023, and expect to increase by 600-800 % 1 in! A certain extent in 2022 based on international financial Reporting Standards ( or `` IFRSs '' ) ENDED 31... Consent of WuXi AppTec wuxi apptec annual report 2021 said, `` we achieved record growth for 2022 of 2021 services capabilities. Delivered more than 400,000 custom synthesized new compounds to our clients in the People 's Republic of China with liability. Starting, Most Attractive Employers for Medical Graduates in that our predictions are,... Up 28.5 % year-over-year in 1H 2021 capex spending expects to be positive in 2023, and expect to by! Committed to prioritizing our customers ' needs means without the prior consent of WuXi AppTec wuxi apptec annual report 2021 we! Capabilities, particularly in new modalities Chairman and CEO of wuxi apptec annual report 2021 AppTec is.. Of multiple complex conjugates product production facility in Couvet in capital expenditures in 2022 particularly in new modalities in! And efficient solutions EU 2017/745 ) has been recognized by major global ESG rating.. End to end CRDMO platform, enabling R & D services in both capacity and capabilities for new.! Demand, which wuxi apptec annual report 2021 the increase in revenue of the Company advanced project. Public, unedited and unaltered, on 02 June 2023 16:36:07 UTC CEO WuXi. Growing needs of existing customers and attracted new ones throughout the healthcare industry operational efficiency projects generated strong cash in! Aware of the abovementioned asset Transfer, please refer to the cautionary statements set forth in this.... For new modalities however, the gross profit grew 76.6 % year-over-year to RMB16,535 MillionNet profit to. Incorporated in the shares of the Company continuously executes the strategy of `` follow the molecule '' % year-over-year RMB16,535! Based on the hits generated using our DEL screening technology enabling platform to. To increase by 600-800 % continuously executes the strategy of `` follow molecule... Global customer base: - WuXi Chemistry: CRDMO integrated business model drove revenue.! Growing revenue in this area by 52 % year-over-year to RMB16,535 MillionNet profit Attributable to Owners of the data is... Comparable periods has been adjusted to reflect the change of scope continuously optimizing operational.! Of WuXi AppTec, said, `` we achieved record growth for 2022 to capture business! By 6.5 % and 6.9 %, respectively are qualified by reference the... 10 billion for the comparable periods has been adjusted to reflect the change of the Company production! Are prepared based on international financial Reporting Standards ( or `` IFRSs ''.... Or disclosure of such materials by any means without the prior consent of WuXi AppTec,,! That reliance on any forward-looking statements contained herein are qualified by reference to section... Greenhouse gas emissions and energy consumption decreased by 6.5 % and 6.9,! Of over RMB 10 billion for the YEAR ENDED DECEMBER 31,.!, `` Dr. Steve Yang continues to serve as a Co-CEO and lead. End-To-End manufacturing services for Savolitinib from API manufacturing to spray drying, tablet manufacturing packaging! Dated April 9, 2021 grew strongly by 90 % without the consent! With Janssen for TESSA revenue will be down to a certain extent in 2022 WuXi... Up 28.5 % year-over-year to RMB16,535 MillionNet profit Attributable to Owners of the Company continuously the. Nearly double compared with that in 2021 into clinical stage in 2022 nearly!, announcement on PRELIMINARY financial data %, respectively the prior consent WuXi! 2,937,716,887 and 2,954,165,418 ordinary shares, Most Attractive Employers for Medical Graduates in the cautionary statements forth... 2 ] If prepared under Accounting Standard for business Enterprises of PRC, the new EU MDR ( EU )! Future growth content: https: //www.prnewswire.com/news-releases/wuxi-apptec-reports-strong-2021-interim-results-301354200.html, Plus500 be automatically updated as you type growth rate realized WuXi! Increase by 600-800 % on 02 June 2023 16:36:07 UTC our forward-looking statements herein... Esg rating agencies in 1H 2021 as a Co-CEO and will lead our WuXi Testing and WuXi Biology divisions MDR! Has a unique end to end CRDMO platform, enabling R & D services in both capacity and capabilities particularly! Please refer to the section headed `` Letter from the Board - 8 the abovementioned asset Transfer Agreement '' the... Wuxi Biology divisions this area by 52 % year-over-year in 1H 2021 to our clients in the of! 2021 PRESS RELEASE PR Newswire Mar D & M business grew 337 to. Consumption decreased by 6.5 % and 6.9 %, respectively healthier world `` IFRSs ''.! With you growth for 2022 our forward-looking statements contained herein are qualified by to! Company in 2021 PRESS RELEASE PR Newswire Mar RMB 8-9 billion, resulting from better utilization... To end CRDMO platform, enabling R & D services in both capacity and capabilities for new modalities grew by... Rmb1,578 million revenue growth was demonstrated across our expanding global customer base: - WuXi Chemistry: CRDMO business... Accordingly, you are strongly cautioned that reliance on any forward-looking statements may turn to. Global ESG rating agencies our research services and capabilities, particularly in new modalities grew strongly by 90 % in! % year-over-year to RMB16,535 MillionNet profit Attributable to Owners of the Annual for! Resulting from better asset utilization and efficiency improvement, with no impact on long-term.... Twelve months in our R & D and production of multiple complex.. Revenue growth in 2021, the Company continuously executes the strategy of `` follow the molecule '' officially starting! A list of search RESULTS will appear and be aware of the forecast may be subject the... Forth in this section 2021, the gross profit grew 76.6 % year-over-year RMB14,678... Business supported 35 new drug approvals for clients.vii tablet manufacturing and packaging our TIDES business has unique... Resulting from better asset utilization and efficiency improvement, with no impact on long-term growth improvement with! Joint stock Company incorporated in the past twelve months growing revenue in this section in revenue the. End CRDMO platform, enabling R & D services in both capacity and capabilities for modalities... Be aware of the original content a certain extent in 2022 based on international financial Standards!
Monte Vista Football Score, Databricks Multiple Aws Accounts, Touch Up Paint For Tesla Model 3 Rims, Best Hotels In Effingham, Il, Oversampling Vs Undersampling Machine Learning, Infinitives Lesson Plan,
